Cardiomyopathy — disease of the heart muscle itself — is a CDL condition that covers a spectrum from well-controlled chronic heart failure on oral medications to end-stage heart disease requiring devices, transplantation workup, and repeated hospitalisation. Medical aid cover for cardiomyopathy has improved significantly in recent years as new evidence-based treatments have become standard of care, but several high-cost items remain disputed between schemes and treating cardiologists.
What Is Cardiomyopathy?
Cardiomyopathy refers to structural and functional abnormality of the heart muscle not primarily caused by coronary artery disease or valvular pathology. The main types:
- Dilated cardiomyopathy (DCM): Enlarged, weakened left ventricle; most common type in SA.
- Hypertrophic cardiomyopathy (HCM): Thickened heart muscle; significant sudden cardiac death risk.
- Restrictive cardiomyopathy: Stiffened ventricle; impaired filling.
- Arrhythmogenic right ventricular cardiomyopathy (ARVC): Fibrous replacement of right ventricular muscle; arrhythmia risk.
The key metric is ejection fraction (EF) — the percentage of blood the left ventricle pumps out with each beat. Normal: 55–70%. Heart failure with reduced ejection fraction (HFrEF, EF <40%) is the most common scenario requiring intensive pharmacological and device therapy.
CDL and PMB Coverage
Cardiomyopathy is a Chronic Disease List (CDL) condition. Your medical aid must: - Fund CDL-registered medications for cardiomyopathy management indefinitely. - Cover acute decompensated heart failure hospitalisations under PMB. - Fund implantable devices (ICD, CRT-D) where medically indicated under PMB.
Register your diagnosis with the scheme's chronic disease department as soon as possible. CDL registration protects your medication costs from depleting your medical savings account.
Treatment: The Four-Pillar Drug Protocol
For HFrEF, international guidelines (ESC, HFSA, SAJHM) recommend four foundational medication classes — often called the "four pillars":
- Beta-blocker (carvedilol, bisoprolol, metoprolol) — reduces heart rate and cardiac workload.
- ACE inhibitor or ARB (enalapril, ramipril, perindopril) — reduces cardiac remodelling.
- Mineralocorticoid receptor antagonist — MRA (spironolactone, eplerenone) — reduces fluid retention and mortality.
- SGLT2 inhibitor (empagliflozin/Jardiance or dapagliflozin/Forxiga) — recently proven to reduce HF hospitalisations and mortality independently of diabetes status.
A fifth agent — sacubitril/valsartan (Entresto) — replaces the ACE inhibitor in patients who tolerate it, and carries a strong mortality-reduction evidence base. Cost: approximately R3,500/month. Some schemes fund Entresto under CDL; others require exceptional-needs motivation.
Implantable Devices: The High-Cost Events
ICD (Implantable Cardioverter-Defibrillator): Indicated in HFrEF (EF <35%) and in hypertrophic cardiomyopathy for sudden cardiac death prevention. Device cost: R80,000–R150,000. Implantation procedure adds R30,000–R60,000 in hospital and specialist fees before shortfall.
CRT-D (Cardiac Resynchronisation Therapy + Defibrillator): Indicated in HFrEF with LBBB (left bundle branch block) — synchronises the two ventricles to improve cardiac output. More complex than ICD implantation; device cost R150,000–R250,000. Pre-authorisation with detailed clinical motivation is required.
Important: Device funding comes from the in-hospital benefit, not the CDL benefit. Confirm whether your plan has a separate device sub-limit or whether the device cost is covered under the general in-hospital benefit.
Medication Costs
Estimated; SAHPRA SEP verification pending.
| Medication | Class | Estimated Monthly Cost |
|---|---|---|
| Carvedilol / Bisoprolol | Beta-blocker | R250–R400 |
| Enalapril / Ramipril | ACE inhibitor | R200–R300 |
| Spironolactone | MRA | R300–R400 |
| Furosemide | Loop diuretic | R100–R200 |
| Sacubitril/Valsartan (Entresto) | ARNI | R3,000–R4,000 |
| Empagliflozin (Jardiance) | SGLT2 inhibitor | R1,000–R1,400 |
Annual Cost Estimates
| Scenario | Estimated Annual Cost |
|---|---|
| Stable HFrEF, four-pillar oral therapy | R15,000 – R45,000 |
| HFrEF + Entresto + SGLT2 inhibitor | R60,000 – R90,000 |
| ICD implantation event (device + procedure) | R120,000 – R220,000 |
| CRT-D implantation event | R180,000 – R320,000 |
| Advanced HF with recurrent admissions | R200,000 – R350,000+ |
Gap Cover and Specialist Shortfalls
Cardiomyopathy's gap cover exposure is concentrated at: - Cardiologist consultations — specialist billing above tariff on quarterly or more frequent reviews. - Device implantation — electrophysiologist or interventional cardiologist billing above tariff. - Acute heart failure hospitalisation — cardiologist inpatient fee shortfall on each day of admission.
The gap OPL (~R220,000/year) is generally adequate for stable cardiomyopathy with one device event. Patients with recurrent decompensations requiring multiple hospitalisations can accumulate shortfalls that approach or exceed the OPL.
The Entresto and SGLT2 Inhibitor Funding Question
These two agents represent the biggest current coverage controversy in cardiomyopathy management:
-
Entresto (sacubitril/valsartan): ESC guidelines recommend Entresto as first-line for HFrEF ahead of plain ACE inhibitors. Some SA schemes have updated CDL formularies to include it; others still require exceptional-needs. If your scheme declines Entresto, ask your cardiologist to submit a motivation referencing the ESC 2021 guidelines and PARADIGM-HF trial data.
-
SGLT2 inhibitors for HF (empagliflozin, dapagliflozin): Evidence from EMPEROR-Reduced and DAPA-HF trials established these for HFrEF regardless of diabetic status. CDL classification for the non-diabetic HF indication varies widely across SA schemes. Exceptional-needs motivation with trial data is typically required.
Disease Management Programmes
Most SA medical aid schemes offer a heart failure disease management programme (DMP) for members with cardiomyopathy and heart failure. These programmes provide: - Dedicated nurse case management with telephonic check-ins - Enhanced benefit access in some schemes (e.g., additional outpatient visits, better access to specialist consultations) - Coordinated pre-authorisation support for devices and medications - Early warning protocols to prevent unnecessary acute admissions
Enrolment in a DMP does not limit your treatment choices but can significantly improve the administrative experience of managing a chronic cardiac condition. Ask your scheme whether a heart failure or cardiovascular DMP is available and how to enrol.
Talk to Eldon
See which plans pay for cardiomyopathy →
This page is general information about medical schemes. It is not medical advice: speak to a healthcare professional about your own treatment. Medical aid and gap cover advice is given by Eldon de Waal, a Supervised Representative of Approach Administration (FSP 23579).